MAY 06, 2021 6:30 AM PDT

COVID Vaccines Don't Protect Everyone

WRITTEN BY: Tara Fernandez

New research has revealed that COVID-19 vaccines may not work as effectively in those whose immune systems have been negatively impacted by underlying medical conditions or the drugs used to treat those conditions.

These findings are not entirely surprising. For instance, previous investigations in immunocompromised people had pointed towards the possibility that vaccines may not perform optimally in these populations. In the VACANCE study of 2012, for example, less than half of the participants (who were cancer patients undergoing chemotherapy) produced antibodies to influenza after receiving the vaccine.

Based on these and other findings, scientists were seeking answers on whether similarly low immune responses would be observed when these vulnerable groups got the COVID-19 vaccination. So far, evidence is supporting this theory. A Johns Hopkins University study in which patients who were the recipients of organ transplants showed poor antibody responses to the Pfizer-BioNTech and Moderna vaccines—a mere 17% of the participants showed detectable levels of antibodies against SARS-CoV-2.

Similar results have also been reported in those with autoimmune conditions. Data published on the preprint server medRxiv indicated that on average, the participants who were on medications to manage chronic inflammatory diseases produced about one-third as many antibodies as healthy individuals who receive the COVID vaccine.

“CID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses,” wrote the authors.

For now, ways to improve immune responses for these at-risk groups are still being explored. Additional doses of the standard COVID vaccinations, mixing vaccines, or the use of monoclonal antibodies, have been proposed as possible solutions for protecting these patients.

 


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JAN 26, 2021
Immunology
Can we Stop Multiple Sclerosis Progression?!
JAN 26, 2021
Can we Stop Multiple Sclerosis Progression?!
Multiple sclerosis is known for its progression of symptoms even after a period of complete remission. There is no way o ...
JAN 28, 2021
Immunology
Killers With a Hit on the Spike
JAN 28, 2021
Killers With a Hit on the Spike
Natural killer cells, or NK cells, are specialized immune cells of the innate immune system. Their job revolves around e ...
MAR 11, 2021
Immunology
Bye-Bye Burning: A New UTI Vaccine
MAR 11, 2021
Bye-Bye Burning: A New UTI Vaccine
Researchers have developed a vaccine that “trains” the bladder to fight back against the bacteria that cause ...
APR 29, 2021
Immunology
A Week for World Immunization
APR 29, 2021
A Week for World Immunization
The World Health Organization (WHO) is calling our attention to World Immunization Week, which comes in the last week of ...
MAY 17, 2021
Cell & Molecular Biology
Survey Results: Where Is Pluripotent Stem Cell Research Now?
MAY 17, 2021
Survey Results: Where Is Pluripotent Stem Cell Research Now?
Human pluripotent stem cell (hPSC) lines are now commonly used across the globe. In the lab, researchers rely on hPSCs t ...
JUN 03, 2021
Immunology
Inhalable Anti-COVID Nanobodies Show Promising Results in Hamsters
JUN 03, 2021
Inhalable Anti-COVID Nanobodies Show Promising Results in Hamsters
Nanobodies are small fragments of monoclonal antibodies that from a therapeutic perspective are more stable and cheaper ...
Loading Comments...